Drug Addiction - Pipeline Review, H2 2017

  • ID: 4337670
  • Report
  • 162 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCorRx Inc
  • Curemark LLC
  • Heptares Therapeutics Ltd
  • Kyowa Hakko Kirin Co Ltd
  • P2D Bioscience
  • MORE
Drug Addiction - Pipeline Review, H2 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • BioCorRx Inc
  • Curemark LLC
  • Heptares Therapeutics Ltd
  • Kyowa Hakko Kirin Co Ltd
  • P2D Bioscience
  • MORE
Introduction

Drug Addiction - Overview

Drug Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Drug Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Addiction - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Aelis Farma SAS

Aphios Corp

BioCorRx Inc

Cerecor Inc

Chiesi Farmaceutici SpA

Curemark LLC

Egalet Corp

Embera NeuroTherapeutics Inc

F. Hoffmann-La Roche Ltd

Foresee Pharmaceuticals LLC

Heptares Therapeutics Ltd

Immunovaccine Inc

Indivior Plc

InterveXion Therapeutics LLC

Intra-Cellular Therapies Inc

Kyorin Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

P2D Bioscience

Saniona AB

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd

Zynerba Pharmaceuticals Inc

Drug Addiction - Drug Profiles

(acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile

(hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile

(metyrapone + oxazepam) - Drug Profile

18-MC - Drug Profile

ADX-71441 - Drug Profile

ADX-71743 - Drug Profile

ADX-88178 - Drug Profile

AEF-0117 - Drug Profile

ANS-6637 - Drug Profile

AT-076 - Drug Profile

AT-089 - Drug Profile

AT-1001 - Drug Profile

AT-212 - Drug Profile

Biologic to Agonize TLR4 for Drug Addiction - Drug Profile

cannabidiol - Drug Profile

CERC-501 - Drug Profile

CM-1212 - Drug Profile

DDD-024 - Drug Profile

dronabinol - Drug Profile

dronabinol - Drug Profile

Drug for Addiction - Drug Profile

Enzyme for Cocaine Addiction - Drug Profile

EORA-101 - Drug Profile

EP-11313 - Drug Profile

FP-004 - Drug Profile

Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile

h-2E2 - Drug Profile

ibudilast - Drug Profile

istradefylline - Drug Profile

ITI-333 - Drug Profile

IXT-m200 - Drug Profile

JDTic - Drug Profile

JQ-1 - Drug Profile

KDAC-0001 - Drug Profile

levofacetoperane - Drug Profile

lofexidine hydrochloride - Drug Profile

MC-100093 - Drug Profile

naltrexone hydrochloride SR - Drug Profile

NLS-10 - Drug Profile

NS-2359 - Drug Profile

OMS-405 - Drug Profile

OMS-527 - Drug Profile

OPNT-001 - Drug Profile

OREX-1019 - Drug Profile

OREX-1038 - Drug Profile

oxycodone hydrochloride - Drug Profile

RBP-8000 - Drug Profile

Recombinant Enzyme for Cocaine Abuse - Drug Profile

RO-5256390 - Drug Profile

SERx-480 - Drug Profile

Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Small Molecules for Neonatal Abstinence Syndrome - Drug Profile

Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile

Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile

Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile

Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile

Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile

Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile

Vaccine for Cocaine Addiction - Drug Profile

Vaccine for Drug Abuse - Drug Profile

Vaccine for Methamphetamine Abuse - Drug Profile

Vaccine for Methamphetamine Addiction - Drug Profile

VU-0463841 - Drug Profile

Drug Addiction - Dormant Projects

Drug Addiction - Discontinued Products

Drug Addiction - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Drug Addiction, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2

Drug Addiction - Pipeline by Aelis Farma SAS, H2

Drug Addiction - Pipeline by Aphios Corp, H2

Drug Addiction - Pipeline by BioCorRx Inc, H2

Drug Addiction - Pipeline by Cerecor Inc, H2

Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H2

Drug Addiction - Pipeline by Curemark LLC, H2

Drug Addiction - Pipeline by Egalet Corp, H2

Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2

Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H2

Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2

Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H2

Drug Addiction - Pipeline by Immunovaccine Inc, H2

Drug Addiction - Pipeline by Indivior Plc, H2

Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H2

Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H2

Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2

Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H2

Drug Addiction - Pipeline by Omeros Corp, H2

Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2

Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H2

Drug Addiction - Pipeline by P2D Bioscience, H2

Drug Addiction - Pipeline by Saniona AB, H2

Drug Addiction - Pipeline by Stada Arzneimittel AG, H2

Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2

Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2

Drug Addiction - Dormant Projects, H2

Drug Addiction - Dormant Projects, H2 2017 (Contd..1), H2

Drug Addiction - Dormant Projects, H2 2017 (Contd..2), H2

Drug Addiction - Discontinued Products, H2

List of Figures:

Number of Products under Development for Drug Addiction, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Addex Therapeutics Ltd
  • Aelis Farma SAS
  • Aphios Corp
  • BioCorRx Inc
  • Cerecor Inc
  • Chiesi Farmaceutici SpA
  • Curemark LLC
  • Egalet Corp
  • Embera NeuroTherapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Foresee Pharmaceuticals LLC
  • Heptares Therapeutics Ltd
  • Immunovaccine Inc
  • Indivior Plc
  • InterveXion Therapeutics LLC
  • Intra-Cellular Therapies Inc
  • Kyorin Pharmaceutical Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • P2D Bioscience
  • Saniona AB
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll